Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
Spotlight
GLP-1s
Interviews
FDA
Strategy
Generics
Biosimilars
Value Added Medicines
Business
Deals
Earnings
Manufacturing
Policy & Regulation
Regulatory Landscape
Drug Pricing
IP & Litigation
Tools & Trackers
What's Next?
Who's Hired?
UK Pricing Tracker
Company Rankings
Podcasts
Conference Coverage
Partner Insights
Generics Bulletin Perspectives
Exploring market-shifting topics for the off-patent sector.
View
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
Teva Prepares To Launch LAI Risperidone After US Approval
MedinCell-Partnered Schizophrenia Treatment Uzedy Has Now Been Approved By US FDA
May 02 2023
•
By
David Wallace
The FDA has approved Teva and MedinCell’s LAI risperidone as Uzedy • Source: Shutterstock
More from Products
More from Generics Bulletin